Interestingly, TLR-4 is the most popular among the TLRs evaluated as receptors in numerous clinical trials as a potential target for immunotherapy against various pathologies concerning inflammation, viral infection, immune diseases, and cancers (Table 3) [186,187,188]. This evidence concerns the gene TLR4 and cancer.